{"schema_version":"secwatch.filing_event.v1","accession":"0000078003-26-000094","form_type":"8-K","ticker":"PFE","cik":"0000078003","company_name":"PFIZER INC","filed_at":"2026-08-04T11:02:43+00:00","discovered_at":"2026-08-04T11:05:00.386483+00:00","generated_at":"2026-08-04T11:05:28.345760+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Pfizer Q2 2026: Revenue $15.0B, raises FY guidance midpoint by $500M, reports net loss on $4.3B impairments","bullets":["Q2 revenue $15.0B (+1% operational); launched/acquired products grew 18% operationally.","Reported net loss $248M ($0.04 LPS) from $4.3B impairments; adjusted EPS $0.77 flat YoY.","Raises FY2026 revenue guidance to $60.5-$62.5B (midpoint +$500M); reaffirms adjusted EPS $2.80-$3.00.","Announces additional $2.5B in productivity savings from 2027-2029; ongoing cost realignment program.","Pipeline: Lorbrena 7-yr PFS HR 0.19, Padcev MIBC approval, Litfulo vitiligo Phase 3 positive, sigvotatug vedotin miss."],"urls":{"canonical":"https://secwatch.observer/filing/0000078003-26-000094","json":"https://secwatch.observer/filing/0000078003-26-000094.json","markdown":"https://secwatch.observer/filing/0000078003-26-000094.md","text":"https://secwatch.observer/filing/0000078003-26-000094.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/78003/000007800326000094/0000078003-26-000094-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/78003/000007800326000094/pfe-20260804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-04T11:05:28.345760+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}